Immunocore Holdings plc (6YG)
TG
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.8 | 2.75862068966 | 29 | 29 | 29 | 50 | 29 | DE |
4 | 1.8 | 6.42857142857 | 28 | 29 | 27.4 | 76 | 27.7480315 | DE |
12 | -1.4 | -4.48717948718 | 31.2 | 32.6 | 27.4 | 40 | 29.35242019 | DE |
26 | -5.6 | -15.8192090395 | 35.4 | 37.4 | 27.4 | 60 | 31.40230854 | DE |
52 | -38.7 | -56.496350365 | 68.5 | 71 | 27.4 | 55 | 38.89281424 | DE |
156 | -22.7 | -43.2380952381 | 52.5 | 71 | 27.4 | 53 | 41.7049288 | DE |
260 | -22.7 | -43.2380952381 | 52.5 | 71 | 27.4 | 53 | 41.7049288 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.